- Next-generation mRNA vaccines will be easier to use: Moderna CEO Yahoo Finance
- Moderna’s flu-Covid combo vaccine elicits ‘strong’ immune response in Phase 1/2 study, company says CNN
- What’s Going On With Moderna Stock Wednesday? – Moderna (NASDAQ:MRNA) Benzinga
- Moderna CEO on combo Covid, flu vaccine moving to next trial phase Yahoo Finance
- Self-amplifying mRNA seasonal influenza vaccines elicit mouse neutralizing antibody and cell-mediated immunity and protect ferrets | npj Vaccines Nature.com
- View Full Coverage on Google News
Tag Archives: Moderna
Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading – CNBC
- Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading CNBC
- Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data Yahoo News
- Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data Reuters
- Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Yahoo Finance
- View Full Coverage on Google News
Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 – Endpoints News
- Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 Endpoints News
- Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading CNBC
- Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data KSL.com
- Moderna and Merck reveal new data on individualized cancer treatment MarketWatch
- Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Yahoo Finance
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – Moderna Investor Relations
- Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano Moderna Investor Relations
- AACR 2023 – more hope for Moderna’s neoantigen immunotherapy Evaluate Pharma
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
- Phase 2 Data of Personalized Cancer Vaccine With Adjuvant Pembrolizumab for Resected High-Risk Melanoma Dermatology Times
- Merck clashes with AstraZeneca in biliary tract cancer FiercePharma
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – news.modernatx.com
- Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano news.modernatx.com
- Including Anti-PD-1 in First-Line Ups Survival in Biliary Tract Cancer Medpage Today
- AACR 2023 – more hope for Moderna’s neoantigen immunotherapy evaluate.com
- Phase 2 Data of Personalized Cancer Vaccine With Adjuvant Pembrolizumab for Resected High-Risk Melanoma Dermatology Times
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
- View Full Coverage on Google News
Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more – CNBC
- Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more CNBC
- Latest Stock Market News Today: First Republic, bank stocks sink after Silicon Valley Bank gets emergency funds from Fed, FDIC, Treasury. | March 13, 2023 | Live Updates from Fox Business
- First Republic tells CNBC the bank isn’t seeing that many depositors leave CNBC Television
- First Republic drops 60%, leads decline in bank stocks despite government’s backstop of SVB CNBC
- Customers Line Up Outside First Republic Bank Branch After SVB Collapse KPRC 2 Click2Houston
- View Full Coverage on Google News
Moderna Stock Skids After 2023 Guidance Misses By More Than $2 Billion – Investor’s Business Daily
- Moderna Stock Skids After 2023 Guidance Misses By More Than $2 Billion Investor’s Business Daily
- Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand CNBC
- Sliding vaccine sales, new costs, shrink Moderna 4Q profit Yahoo Finance
- Moderna co-founder talks COVID-19 vaccines, mRNA growth, agriculture portfolio Yahoo Finance
- Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half MarketWatch
- View Full Coverage on Google News
Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand – CNBC
- Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand CNBC
- Sliding vaccine sales, new costs, shrink Moderna 4Q profit Yahoo Finance
- Moderna co-founder talks COVID-19 vaccines, mRNA growth, agriculture portfolio Yahoo Finance
- Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half MarketWatch
- Moderna stock dips as Q4 earnings fall; reaffirms COVID vaccine sales outlook of $5B Seeking Alpha
- View Full Coverage on Google News
Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine – Investor’s Business Daily
- Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine Investor’s Business Daily
- Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag Reuters
- Moderna expands CRISPR gene editing research with ElevateBio partnership The Boston Globe
- Moderna taps Life Edit to develop next-gen gene therapies FierceBiotech
- Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients Yahoo Finance
- View Full Coverage on Google News
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations
- Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients Moderna Investor Relations
- Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine Investor’s Business Daily
- Moderna expands CRISPR gene editing research with ElevateBio partnership The Boston Globe
- Moderna’s combination skin cancer therapy receives FDA’s breakthrough tag Reuters
- Moderna taps Life Edit to develop next-gen gene therapies FierceBiotech
- View Full Coverage on Google News